Press coverage about Tobira Development (NASDAQ:TBRA) has been trending somewhat positive on Friday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tobira Development earned a news impact score of 0.06 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.1602146371198 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Tobira Development (TBRA) opened at $42.09 on Friday. Tobira Development has a fifty-two week low of $3.76 and a fifty-two week high of $42.33. The company has a quick ratio of 5.38, a current ratio of 5.38 and a debt-to-equity ratio of 0.44.
TRADEMARK VIOLATION NOTICE: “Tobira Development (TBRA) Receives Media Sentiment Rating of 0.06” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/12/tobira-development-tbra-earns-daily-media-sentiment-score-of-0-06.html.
About Tobira Development
Tobira Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company’s product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5) in late stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure.
Receive News & Ratings for Tobira Development Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Development and related companies with MarketBeat.com's FREE daily email newsletter.